Inovio Pharmaceuticals (Inovio Pharmaceuticals) Days Sales Outstanding : 0.00 (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals Days Sales Outstanding?

Inovio Pharmaceuticals's average Accounts Receivable for the three months ended in Dec. 2023 was $0.00 Mil. Inovio Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.10 Mil. Hence, Inovio Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Inovio Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

INO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.45 Med: 123.4 Max: 2470.38
Current: 463.27

During the past 13 years, Inovio Pharmaceuticals's highest Days Sales Outstanding was 2470.38. The lowest was 45.45. And the median was 123.40.

INO's Days Sales Outstanding is ranked worse than
93.14% of 889 companies
in the Biotechnology industry
Industry Median: 71.03 vs INO: 463.27

Inovio Pharmaceuticals's Days Sales Outstanding declined from Dec. 2022 (1,512.93) to Dec. 2023 (0.00).

Inovio Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Inovio Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Days Sales Outstanding Chart

Inovio Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

178.24

474.29

2,470.38

127.49

746.67

Inovio Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															1,512.93	704.21	15.95	1.41	-

Competitive Comparison of Inovio Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Inovio Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inovio Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Days Sales Outstanding falls into.

Inovio Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Inovio Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1.702	+	0)	/	1 )	/	0.832	*	365
=	1.702					/	0.832	*	365
=	746.67

Inovio Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0.103	*	365 / 4
=	0					/	0.103	*	365 / 4
=	0.00

Inovio Pharmaceuticals (NAS:INO) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Inovio Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

INO:Mexico GBMB:Germany GBMB:Germany

Address

660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462

Website

https://www.inovio.com

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Executives

Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
David B. Weiner	director	717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito	director	967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner	officer: Chief Medical Officer	660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau	officer: Chief Scientific Officer	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea	officer: Chief Operating Officer	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies	officer: CFO
Roger D Dansey	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim	director, officer: Chief Executive Officer	660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard	director	15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller	director	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno	director
Morton Collins	director
George Bickerstaff	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai	officer: Chief Operating Officer	VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422